Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction

Castelli, Gian Paolo; Pognani, Claudio; Meisner, Michael; Stuani, Antonio; Bellomi, Daniela; Sgarbi, L.

doi:10.1186/cc2877

Cited by 335 publications

(107 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Although it is considered a non-specific biomarker, research has suggested that patients with an elevated base level of CRP are at a higher risk of diabetes, 2 sepsis, 3 and most importantly, cardiovascular disease. 4 Thus, monitoring CRP levels is considered a useful method of screening and disease management.…”

Section: Introductionmentioning

confidence: 99%

A novel nanozyme assay utilising the catalytic activity of silver nanoparticles and SERRS

Sloan-Dennison

Laing

Shand

et al. 2017

Analyst

View full text Add to dashboard Cite

aArtificial enzymes have become an increasingly interesting area of research due to their many advantages over natural protein enzymes which are expensive, difficult to isolate and unable to stand harsh environments. An important area of this research involves using metal nanoparticles as artificial enzymes, known as nanozymes, which exhibit peroxidase-like activity enabling them to catalyse the oxidation of substrates such as 3,3',5,5'-tetramethylbenzidine (TMB) in the presence of hydrogen peroxide (H2O2), giving a colorimetric response. Here we exploit the catalytic activity of silver nanoparticles (Ag NPs) in a surface based silver-linked immunosorbent assay (SLISA) to detect human C-reactive protein (CRP), an inflammatory marker. Ag NPs were conjugated to antibodies with specific recognition for the corresponding target antigenic molecule, CRP, and the Ag NPs were used to catalyse the oxidation of TMB by H2O2. The resulting coloured oxidation product was detected using SERRS. We demonstrate that Ag NPs can replace the enzymes used in a conventional ELISA and a detection limit of 1.09 ng/mL of CRP can be achieved. It indicates the promise for SLISAs for biomarker detection and opens the way for further assays of this nature to be created. This novel assay has the potential to be optimised to detect lower levels of CRP and can be further extended for the sensitive and specific detection of other relevant biomarkers.

show abstract

Section: Introductionmentioning

confidence: 99%

A novel nanozyme assay utilising the catalytic activity of silver nanoparticles and SERRS

Sloan-Dennison

Laing

Shand

et al. 2017

Analyst

View full text Add to dashboard Cite

show abstract

“…Finally, 86 studies were included after two updated searches in February 2015 and September 2016 (Fig. 1) (Abidi et al 2008; Ahmadinejad et al 2009; Al-Nawas et al 1996; Anand et al 2015; Balc et al 2003; Barati et al 2010; Battista et al 2016; Bell et al 2003; Beqja-Lika et al 2013; Carpio et al 2015; Castelli et al 2004; Clec’h et al 2006; de Pablo et al 2013; Dorizzi et al 2006; Du et al 2003; Endo et al 2012; Farag et al 2013; Feng et al 2012; Gaini et al 2006; Garnacho-Montero et al 2014; Gerrits et al 2013; Giamarellos-Bourboulis et al 2008; Gibot et al 2004; Godnic et al 2015; Guven et al 2002; Han et al 2016; Harbarth et al 2001; Hoenigl et al 2013; Hou et al 2012, 2016; Hsu et al 2011; Ishikura et al 2014; Ivancevic et al 2008; Jekarl et al 2013, 2014; Jiang et al 2015; Kim and Zhang 2012; Kofoed et al 2007; Latour-Perez et al 2010; Lewis et al 2015; Li et al 2013a; Lin et al 2015; Matera et al 2013; Mat-Nor et al 2016; Mearelli et al 2014; Meynaar et al 2011; Miglietta et al 2015; Miller et al 1999; Muthiah et al 2007, Naeini and Montazerolghaem 2006; Oshita et al 2010; Papadimitriou-Olivgeris et al 2015; Ratzinger et al 2013; Reichsoellner et al 2014; Righi et al 2014; Rivera-Chavez and Minei 2009; Rogina et al 2014; Romualdo et al 2014; Ruiz-Alvarez et al 2009; Sakr et al 2008; Scherpereel et al 2006; Schulte et al 2011; Selberg et al 2000; Seok et al 2012; Shozushima et al 2011; Sierra et al 2004; Su et al 2012, 2013; Sungurtekin et al …”

Section: Resultsmentioning

confidence: 99%

Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis

et al. 2016

View full text Add to dashboard Cite

BackgroundSepsis is one of the most common diseases that seriously threaten human health. Although a large number of markers related to sepsis have been reported in the last two decades, the diagnostic accuracy of these biomarkers remains unclear due to the lack of similar baselines among studies. Therefore, we conducted a large systematic review and meta-analysis to evaluate the diagnostic value of biomarkers from studies that included non-infectious systemic inflammatory response syndrome patients as a control group.MethodsWe searched Medline, Embase and the reference lists of identified studies beginning in April 2014. The last retrieval was updated in September 2016.ResultsUltimately, 86 articles fulfilled the inclusion criteria. Sixty biomarkers and 10,438 subjects entered the final analysis. The areas under the receiver operating characteristic curves for the 7 most common biomarkers, including procalcitonin, C-reactive protein, interleukin 6, soluble triggering receptor expressed on myeloid cells-1, presepsin, lipopolysaccharide binding protein and CD64, were 0.85, 0.77, 0.79, 0.85, 0.88, 0.71 and 0.96, respectively. The remaining 53 biomarkers exhibited obvious variances in diagnostic value and methodological quality.ConclusionsAlthough some biomarkers displayed moderate or above moderate diagnostic value for sepsis, the limitations of the methodological quality and sample size may weaken these findings. Currently, we still lack an ideal biomarker to aid in the diagnosis of sepsis. In the future, biomarkers with better diagnostic value as well as a combined diagnosis using multiple biomarkers are expected to solve the challenge of the diagnosis of sepsis.Electronic supplementary materialThe online version of this article (doi:10.1186/s40064-016-3591-5) contains supplementary material, which is available to authorized users.

show abstract

“…This study results concluded that there were significant differences between PCT concentration and the sepsis severity by Mann Whitney test obtained p <0,05. [26] Jeong et al in 2012 explained that PCT concentrations was higher in septic patients than in non-sepsis patients with ratio concentration ratio of 3.2 ng/ml compared to 0.4 ng/ml. [27] Similar results were also obtained by Dorrizi et al 2006 that the PCT concentration in sepsis patients is higher than in non-sepsis treated in the ICU and inpatient with each PCT concentration ratio of 3.18 ng/mL and 0.45 ng/ml.…”

Section: Discussionmentioning

confidence: 99%

Procalcitonin as a Biomarker of Severity Degree in Sepsis Due to Pneumonia

Prima¹

2016

AJIM

View full text Add to dashboard Cite

Abstract:Measuring PCT level can be as the examination having the role to differ the systemic inflammatory response syndrome (SIRS) and sepsis. This study aims to know the PCT level in accessing the sepsis degree at pneumonia patients. This study was an analytical study with cross-sectional design. There were 30 samples obtained since February 2013 until March 2014 at the Emergency Room and Inpatient Room of Internal Medicine Local Public Hospital Dr. Zainoel Abidin Banda Aceh. The sample collection was conducted with quota sampling technique. The data was analysed with Anova and followed with LDS. The data was considered to be significant if the p value is < 0,05. The study results were obtained the minimum limit value of PCT level at pneumonia of 0,091 ng/dl, sepsis of 0,686 ng/dl, severe sepsis of 3,593 ng/dl and shock sepsis of 21,703 ng/dl. The analysis results showed that the higher PCT level makes the higher disease severity.

show abstract

Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction

Cited by 335 publications

References 38 publications

A novel nanozyme assay utilising the catalytic activity of silver nanoparticles and SERRS

A novel nanozyme assay utilising the catalytic activity of silver nanoparticles and SERRS

Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis

Procalcitonin as a Biomarker of Severity Degree in Sepsis Due to Pneumonia

Contact Info

Product

Resources

About